

		EMLc	ATC codes: <a href="#">L01CA02</a>
Indication	Malignant neoplasms of kidney, except renal pelvis	ICD11 code: <a href="#">2D40.Z</a>	
INN	Vincristine		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate) ; 5 mg in vial (vincristine sulfate) ; 1 mg per mL in vial (vincristine sulfate) ; 2 mg per 2 mL in vial (vincristine sulfate)		
EML status history	First added in 2011 ( <a href="#">TRS 965</a> ) Changed in 2015 ( <a href="#">TRS 994</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Tags	<a href="#">Cancer</a>		
Wikipedia	<a href="#">Vincristine</a> 		
DrugBank	<a href="#">Vincristine</a> 		

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.

[Expert Committee report](#) 

